Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine

AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.